Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 1,873 participants who were divided into three groups. The first group (625 people) received a placebo plus the chemotherapy drugs paclitaxel and carboplatin. The second group (625 people) received the same chemotherapy plus the drug bevacizumab, alongside a placebo. The third group (623 people) received paclitaxel, carboplatin, and bevacizumab without a placebo. The trial was primarily measuring how long participants went without their disease getting worse (called "progression-free survival"), and also looked at how long participants lived overall, side effects, and quality of life. The reported data shows that the median time before the disease got worse was 11.0 months in the first group, 12.3 months in the second group, and 15.3 months in the third group. For overall survival — meaning the middle point of how long participants lived — the figures reported were 40.6 months for the first group, 38.7 months for the second group, and 43.8 months for the third group. Regarding serious side effects (graded as severe or above), the reported data shows these were recorded across all three groups, though the way this data was submitted makes a straightforward comparison difficult to present cleanly. For quality of life, participants were scored on a scale from 0 to 104 (where a higher number means better quality of life). The reported data shows scores across multiple time points were broadly similar across all three groups, ranging roughly from the high 60s at the start to around 80 at later points. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 37185961) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer through a tissue biopsy, at an advanced stage (stage III with remaining visible tumour, or stage IV), confirmed after initial abdominal surgery
- People whose cancer is one of several specific cell types, including serous, endometrioid, mucinous, undifferentiated, clear cell, mixed epithelial, transitional cell, malignant Brenner's tumour, or adenocarcinoma not otherwise specified — as long as it is consistent with a primary Müllerian epithelial cancer
- People whose white blood cell levels (specifically neutrophils) are at an acceptable level without the use of growth-stimulating medications
- People whose platelet counts are within an acceptable range
- People whose kidney function, as measured by a blood test, is within an acceptable range
- People whose liver function tests (bilirubin, SGOT, and alkaline phosphatase) are within acceptable ranges
- People who have little to no nerve damage (numbness, tingling, or weakness) at the time of joining
- People whose blood clotting tests are within acceptable ranges (including those on a stable dose of warfarin for a blood clot condition)
- People who have a performance status rated 0, 1, or 2 on the GOG scale, meaning they are able to carry out daily activities with little to no restriction
- People who are enrolled between 1 and 12 weeks after their initial surgery for diagnosis, staging, and tumour removal
- People with either measurable or non-measurable disease, with or without cancer-related symptoms
- People who have signed an approved consent form allowing their personal health information to be shared for the study
- People who may receive low-dose oestrogen with or without progestin hormone replacement therapy to manage menopause symptoms during the trial (but not progestins for appetite, while on study treatment or before disease progression)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People currently diagnosed with a borderline (low malignant potential) ovarian tumour, or those with recurrent invasive ovarian, peritoneal, or fallopian tube cancer treated with surgery only — unless they previously had a borderline tumour that was removed and later developed a completely new invasive cancer, and have not had prior chemotherapy for any ovarian tumour
- People who have previously had radiation therapy to any part of the abdomen or pelvis (prior radiation to the breast, head and neck, or skin may be acceptable if it was completed more than three years ago and the cancer has not returned)
- People who have received prior chemotherapy for any abdominal or pelvic tumour, including chemotherapy given before surgery for their ovarian, peritoneal, or fallopian tube cancer (prior chemotherapy for early-stage breast cancer may be acceptable if completed more than three years ago and the cancer has not returned)
- People who have received any targeted therapy (such as vaccines, antibodies, or tyrosine kinase inhibitors) or hormonal therapy for their ovarian or peritoneal cancer
- People with a current or past diagnosis of uterine (endometrial) cancer, unless it was early-stage, had only shallow invasion into the uterine wall, had no spread into blood or lymph vessels, and was not an aggressive tumour type
- People with a history of another invasive cancer (other than certain skin cancers and the exceptions described above) with any evidence of that cancer in the past five years, or whose prior cancer treatment would make this study's treatment unsafe
- People with active hepatitis or a current serious infection requiring intravenous antibiotics
- People with a serious wound that is not healing, an active ulcer, or a bone fracture — including a history of an abnormal opening in the bowel, a bowel perforation, or an infection inside the abdomen within the past 28 days (people with a healing wound may still be considered but would need weekly wound checks)
- People with active bleeding or a medical condition that carries a high risk of bleeding, such as a known bleeding disorder or a tumour near major blood vessels
- People with a history or current signs of brain or nervous system conditions, including a primary brain tumour, poorly controlled seizures, brain metastases, or a stroke or brain bleed within the past six months
- People with significant heart or blood vessel problems, including: uncontrolled high blood pressure (above 150/90 mmHg); a heart attack or unstable chest pain within the past six months; moderate or severe heart failure; a serious heart rhythm problem requiring medication; significant circulation problems in the limbs; or a stroke within the past six months
- People with a known allergic reaction to products derived from Chinese hamster ovary cells or similar laboratory-produced antibodies
- People with significant levels of protein in their urine, as measured by a urine test (a protein-to-creatinine ratio of 1.0 or higher would make someone ineligible)
- People who have had a major surgery, open biopsy, or significant injury within 28 days before the start of the study drug (second treatment cycle), or who are expected to need major surgery during the study
- People who have had a core biopsy within 7 days before the start of the study drug (second treatment cycle)
- People with a GOG performance status of 3 or 4, meaning those who are significantly limited in their daily activities or unable to care for themselves
- People who are pregnant or breastfeeding; people who are able to become pregnant must agree to use contraception during treatment and for at least six months after completing the study drug
- People who have previously received any anti-VEGF therapy, including bevacizumab
- People with signs or symptoms of a bowel blockage who require intravenous fluids or nutrition
- People with other medical conditions that, in the opinion of the study doctor, make participation unsuitable (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Progression-free Survival
Other options
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.